> News > Anergis Appoints Klaus Schollmeier As New Chairman Of The Board Of Directors
24.01
2017

Anergis Appoints Klaus Schollmeier As New Chairman Of The Board Of Directors

EPALINGES, Switzerland, January 24, 2017 – Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.

More information